DJBL (aka EndoBarrier®) is a novel endoscopic duodenal jejunal liner device for obesity, both with and without diabetes. In view of uncertainty re risk vs benefit, during 2017, an independent, secure, online registry was established under the auspices of the Association of British Clinical Diabetologists, for the collection of safety and efficacy data worldwide. As of January 2024, data had been entered on 1101 patients {age 51.3 ± 11.3 years, 52% male, 84% diabetes, BMI 40.9 ± 8.8 kg/m2} and showed many benefits (Table 1). There were 47 (4.3%) SAEs and 146 (13.3%) less serious AEs (Table 2). All SAE patients made a full recovery and most derived significant benefit. The benefits of DJBL therapy are likely to reduce the complications of diabetes. This international data from the DJBL registry suggests that the likely benefits far outweigh the risks.

graphic
View largeDownload slide
graphic
View largeDownload slide
Disclosure

R.E.J. Ryder: Speaker's Bureau; Abbott, Besins Healtcare, BioQuest, GI Dynamics. Consultant; GI Dynamics. Other Relationship; Novo Nordisk. R. Lopez-Gonzalez: None. C. Lazzara: Consultant; Johnson & Johnson Medical Devices Companies. J. Pujol-Gebelli: None. J. Stein: None. T. Battelino: Advisory Panel; Lilly Diabetes. Speaker's Bureau; Lilly Diabetes. Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi. Speaker's Bureau; Sanofi. Advisory Panel; Medtronic. Speaker's Bureau; Medtronic. Advisory Panel; Abbott. Speaker's Bureau; Abbott, Dexcom, Inc. Research Support; Dompé. J.P. Teare: None. A. Ruban: None. M. Haluzik: Advisory Panel; Sanofi, Novo Nordisk, Eli Lilly and Company, AstraZeneca, Bayer Inc., Johnson & Johnson Medical Devices Companies. Consultant; Merck & Co., Inc., Sanofi, Novo Nordisk, Eli Lilly and Company, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Johnson & Johnson Medical Devices Companies, Novatin. Research Support; Sanofi. Speaker's Bureau; Sanofi, Novo Nordisk. L. Munro: None. H. Frydenberg: None. J.J. McMaster: None. S. Fishman: None. R. Stengel: None. R.V. Cohen: Research Support; Medtronic, Johnson & Johnson Medical Devices Companies. Advisory Panel; Medtronic. Speaker's Bureau; Johnson & Johnson Medical Devices Companies. Advisory Panel; Morphic Medical. J.P. Byrne: None. C. de Jonge: None. J. Greve: Advisory Panel; GI Dynamics. Research Support; Bariatric Solutions, Johnson & Johnson Medical Devices Companies. J.C. Mason: None. J.R. Bessell: None. L. Kow: None. H. Sourij: Advisory Panel; Amarin Corporation. Speaker's Bureau; Amgen Inc., Amarin Corporation, Bayer Inc. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Advisory Panel; Eli Lilly and Company. Research Support; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Novartis AG. Speaker's Bureau; Novartis AG. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Sanofi. Speaker's Bureau; Sanofi. Consultant; K:Businesscom. P.N. Pferschy: None. R. Drummond: Speaker's Bureau; Besins Healthcare (UK) Ltd. B. McGowan: Stock/Shareholder; Reset Health. Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Lilly Diabetes. Advisory Panel; Lilly Diabetes. Speaker's Bureau; Amgen Inc. Advisory Panel; Pfizer Inc. S.A. Amiel: Advisory Panel; Vertex Pharmaceuticals Incorporated. Other Relationship; Sanofi. M. Yadagiri: None. P. Sen Gupta: Speaker's Bureau; Novo Nordisk. K. Laubner: Speaker's Bureau; Novo Nordisk, AstraZeneca, Sanofi, MedUpdate GmbH, Germany, Davos Destinations-Organisation, Suisse, Vincentius-Diakonissen-Kliniken gAG, Germany. Other Relationship; Thime Verlag, Germany. Speaker's Bureau; Boehringer-Ingelheim, Lipidliga. J. Seufert: Consultant; Sanofi. Advisory Panel; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim, Sanofi, Lilly Diabetes. Advisory Panel; Abbott. Speaker's Bureau; Abbott, Novo Nordisk. Advisory Panel; Novo Nordisk.

Funding

Association of British Clinical Diabetologists

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.